Drug Trial Radar · NCT05503511
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 20, 2022
Primary completion
Mar 17, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- NeuroPro Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
Conditions
- Epilepsy
- Alzheimer Disease
- Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching PlaceboDrug
Soft gelatin capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: Up to 11 days
- Number of participants with abnormal lab test resultsTime frame: Up to 11 days
- Number of participants with abnormal vital signsTime frame: Up to 11 days
- Number of participants with abnormal ECGTime frame: Up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.